Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2024 Filed Oct 16, 2024 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-025636 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,200 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $54.20 | $108,400.00 |
DisclosureSEC source: 0001127602-24-025636 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,920 Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $54.18 | $287,154.00 |
DisclosureSEC source: 0001127602-24-025636 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,920 Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-025636 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-024720 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $52.09 | $276,077.00 |
DisclosureSEC source: 0001127602-24-024720 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,920 Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-024720 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $52.11 | $104,220.00 |
DisclosureSEC source: 0001127602-24-024720 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,920 Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-024083 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,800 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $56.76 | $113,520.00 |
DisclosureSEC source: 0001127602-24-024083 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,920 Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $56.77 | $300,881.00 |
DisclosureSEC source: 0001127602-24-024083 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,920 Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-024083 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-023334 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $57.02 | $302,206.00 |
DisclosureSEC source: 0001127602-24-023334 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,920 Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,084 | $56.99 | $118,767.16 |
DisclosureSEC source: 0001127602-24-023334 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,920 Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-023334 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-022777 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,400 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $56.26 | $298,178.00 |
DisclosureSEC source: 0001127602-24-022777 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,004 Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-022777 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $56.23 | $112,460.00 |
DisclosureSEC source: 0001127602-24-022777 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,004 Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-021837 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-021837 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $53.70 | $284,610.00 |
DisclosureSEC source: 0001127602-24-021837 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,704 Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $53.74 | $107,480.00 |
DisclosureSEC source: 0001127602-24-021837 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,704 Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 20:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-020876 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 20:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $57.02 | $302,206.00 |
DisclosureSEC source: 0001127602-24-020876 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,004 Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 20:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-020876 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 20:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $57.02 | $114,040.00 |
DisclosureSEC source: 0001127602-24-020876 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,004 Read SEC document |
| July 09, 2024 Filed Jul 9, 2024 22:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-020250 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,300 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2024 Filed Jul 9, 2024 22:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $55.89 | $111,780.00 |
DisclosureSEC source: 0001127602-24-020250 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,004 Read SEC document |
| July 09, 2024 Filed Jul 9, 2024 22:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $55.91 | $296,323.00 |
DisclosureSEC source: 0001127602-24-020250 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,004 Read SEC document |
| July 09, 2024 Filed Jul 9, 2024 22:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-020250 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-019272 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,600 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $53.71 | $284,663.00 |
DisclosureSEC source: 0001127602-24-019272 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,004 Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-019272 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $53.74 | $107,480.00 |
DisclosureSEC source: 0001127602-24-019272 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,004 Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030726 · form4.xml · derivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,422 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-018365 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,900 Underlying: Common Stock · 5,422 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,366 | $53.03 | $125,468.98 |
DisclosureSEC source: 0001127602-24-018365 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,004 Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,422 | $53.05 | $287,637.10 |
DisclosureSEC source: 0001127602-24-018365 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,370 Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,422 | $7.96 | $43,159.12 |
DisclosureSEC source: 0001127602-24-018365 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 7, 2024 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 14,186 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-014445 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,186 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| May 07, 2024 Filed May 7, 2024 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,361 | $65.11 | $88,614.71 |
DisclosureSEC source: 0001127602-24-014445 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,056 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| May 07, 2024 Filed May 7, 2024 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 14,186 | $65.11 | $923,650.46 |
DisclosureSEC source: 0001127602-24-014445 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,417 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| May 07, 2024 Filed May 7, 2024 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 14,186 | $6.67 | $94,620.62 |
DisclosureSEC source: 0001127602-24-014445 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012878 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,417 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 28,605 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-012715 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,605 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $74.32 | $297,280.00 |
DisclosureSEC source: 0001127602-24-012715 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,567 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 28,605 | $74.31 | $2,125,637.55 |
DisclosureSEC source: 0001127602-24-012715 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,567 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 28,605 | $6.67 | $190,795.35 |
DisclosureSEC source: 0001127602-24-012715 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.